<DOC>
	<DOCNO>NCT02654158</DOCNO>
	<brief_summary>Phase IV trial , Single-arm , multi-centre clinical trial ass efficacy safety Fuganlin Oral Liquid child acute upper respiratory infection</brief_summary>
	<brief_title>Phase IV Trial , The Efficacy Safety Study Fuganlin Oral Liquid Children With Acute Upper Respiratory Infection</brief_title>
	<detailed_description>Low-dose group Fuganlin Oral Liquid : dosage 5 10 ml ; High-dose group Fuganlin Oral Liquid : dosage 10 20 ml ; Treatment 1 week.Patients recover within 1 week withdrawal time . Research purpose : 1 . Evaluate safety efficacy Fuganlin oral Liquid expand designate indication ( Qi deficiency wind-heat syndrome wind-heat syndrome ) . 2 . Explore relationship elevate white blood cell efficacy , age efficacy , dose efficacy , While treat Fuganlin oral Liquid child acute respiratory infection . 3 . Observe antiviral immunomodulatory effect Fuganlin oral Liquid . 4 . Provide data support clinical medicine guideline label amendment Fuganlin oral Liquid .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Respiratory Tract Infections</mesh_term>
	<criteria>1 . Patients diagnose acute upper respiratory infection . 2 . Patients acute upper respiratory infection diagnose Tradition Chinese Medicine syndrome qi deficiency windheat . 3 . Patients age 1 12 year old . 4 . Parents guardian agree participate study sign informed consent . 1 . Patients whose total number white blood cell around above1.3ULN . 2 . Patients diagnose suppurative tonsillitis , otitis medium , bronchitis airway . 3 . Patients allergic test drug . 4 . Serious cardiovascular , liver , kidney primary systemic disease . 5 . Patients include group accord investigator 's evaluation .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>acute upper respiratory infection</keyword>
</DOC>